T
T. L. Hsu
Researcher at Taipei Veterans General Hospital
Publications - 7
Citations - 23
T. L. Hsu is an academic researcher from Taipei Veterans General Hospital. The author has contributed to research in topics: Balloon & Mitral valve replacement. The author has an hindex of 3, co-authored 7 publications receiving 23 citations. Previous affiliations of T. L. Hsu include National Yang-Ming University.
Papers
More filters
Journal Article
Response of left ventricular ejection performance following balloon valvuloplasty in patients with mitral stenosis.
TL;DR: A depressed LVEP is frequently seen in patients with MS, and the improvement is not related to the change of preload or afterload but more likely secondary to an increased myocardial contractility.
Journal Article
The Acute and 3-Month Outcomes of Transcatheter Aortic Valve Implantation in Taiwan
Ying-Hwa Chen,T. L. Hsu,Mei-Han Wu,Wen-Chung Yu,Hsiu-Mei Wu,Su-Man Lin,Zen-Chung Weng,Hsiao-Huang Chang +7 more
TL;DR: The immediate and short-term outcomes were encouraging in the first 10 TAVI cases, suggesting multi-specialty collaboration, pre-procedural evaluation with multimodality imaging, and proper patient selection are the cornerstones of success in treating these high-risk patients.
Journal Article
Mitral regurgitation after double balloon or Inoue balloon mitral valvuloplasty.
TL;DR: In conclusion, double balloon and Inoue balloon techniques are both effective in relieving significant mitral stenosis, however, Inoua balloon technique may be associated with slightly higher frequency of mitral regurgitation.
Journal ArticleDOI
Efficacy and safety of slow-release fluvastatin 80 mg daily in Chinese patients with hypercholesterolemia.
TL;DR: In Chinese patients with primary hypercholesterolemia, doubling the dosage of fluvastatin from 40 to 80 mg once daily was effective and safe regarding reduction of LDL cholesterol level, and allowed more patients to achieve LDL cholesterol goals of the NCEP ATP II.
Journal ArticleDOI
Comparison of balloon-expandable valves versus self-expandable valves in high-risk patients undergoing transcatheter aortic valve replacement for severe aortic stenosis
TL;DR: Favorable overall procedural success rates and 30‐day and 6‐month outcomes were achieved with both devices, and it is demonstrated that TAVI using either device is complementary and feasible for treating a wide range of patients by using a careful selection of approaches.